ABOUT / PARTNERS
Partnering at pSivida
As a leader in the development of miniaturized, sustained-release drug delivery systems, pSivida has successfully created partnerships with some of the world’s leading pharmaceutical companies. pSivida seeks strategic partnerships to accelerate development of our existing product pipeline; to access complimentary research, technology and development capabilities; and to expand our product portfolio. We seek to combine our strengths with other organizations and work collaboratively to develop and commercialize therapeutic products and devices.
Current Partnerships
Pfizer
pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. to develop certain ophthalmic products utilizing our drug delivery technology.
Alimera Sciences
pSivida has licensed certain Medidur™ drug delivery technology to Alimera Sciences, Inc. for the development of Iluvien® and certain other ophthalmic products. Iluvien, fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), is pSivida’s lead development product and in December 2009, we announced positive data from the 24 month analysis of the Phase III clinical trials. Based on this data, Alimera Sciences is planning to file a New Drug Application with the U.S. Food and Drug Administration in Q2 2010.
Bausch & Lomb
pSivida has licensed two FDA approved products and their underlying technologies to Bausch & Lomb Incorporated: Retisert® for the treatment of posterior uveitis and Vitrasert® for the treatment of AIDS-related cytomegalovirus (CMV) retinitis.
Partnering Opportunities
pSivida’s technologies have broad applicability across therapeutic areas. Our powerful and validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. pSivida’s intellectual property portfolio consists of over 45 patent families, over 100 granted patents, including patents accepted for issuance, and over 200 patent applications. We evaluate opportunities where we may collaborate with partners to commercialize and/or co-develop therapeutic products utilizing our technology.
For more information regarding partnering with pSivida contact:
businessdevelopment@psivida.com
